Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-M Vaccine Safety and Immunogenicity in Adults
NCT05126979Phase 1Completed
- Sponsor
- Saint Petersburg Scientific Research Institute of Vaccines and Serums
- Start
- Mar 2016
- Primary completion
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen in influenza (3 arms), sponsored by Saint Petersburg Scientific Research Institute of Vaccines and Serums. Primary endpoints: Severity of reported local reactions and their relationship with the vaccination, Severity of reported system reactions and their relationship with the vaccination - during 7 days after the vaccination and 3 more. Started Mar 2016; status: completed.
02
Drugs
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05126979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126979.